The Priority Review

Tag

MRD

1 story

  1. Policy

    Abbott launches whole-genome sequencing Oncodetect MRD test

    Abbott announced the commercial availability of its next-generation Oncodetect MRD test, a personalized, tumor-informed, whole-genome sequencing test that tracks up to 5,000 patient-specific variants with a limit of detection below one part per million. The company said the test could be used for patients with solid tumors.